| abstract |
Use of a compound of formula (I), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use as a Nuclear Factor-kB (NF-kB) inhibitor n nwherein: n nA has the following structure; n n Z is —COOH, —P(O)(OH) 2 or —SO 2 OH; each R 1 is the same or different and is halogen, hydroxy, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 alkoxy, C 1-6 alkylthio, thio, amino, mono(C 1-6 alkyl)amino, di(C 1-6 alkyl)amino, nitro, cyano or —CO 2 R′, wherein R′ represents hydrogen or C 1-6 alkyl; n is 0, 1, 2 or 3; R 2 is hydrogen, C 1-6 alkyl, C 2-6 alkenyl or C 2-6 alkynyl; Y is a linking group; and X is C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, aryl, heteroaryl, carbocyclyl, heterocyclyl, -M-aryl, -M-heteroaryl, -M-carbocyclyl or -M-heterocyclyl, wherein M is C 1-6 alkylene, C 2-6 alkenylene, C 2-6 alkynylene, -Q-Het-Q′- or -Q-Het- wherein Q and Q′ are the same or different and are C 1-6 alkylene, C 2-6 alkenylene or C 2-6 alkynylene and Het is selected from —NR′—, —O—, —S—, —SO 2 —, —SO—, —C(O)—O—, —OC(O), —CO—, —C(O)—NR′— or —NR′—C(O)— wherein R′ is as defined above, provided that: n nwhen n is 0, Z is —COOH, R 2 is hydrogen and Y is —N═N—, X is other than 2-pyridyl. |